OncoMatch/Clinical Trials/NCT04959903
Safety and Efficacy of SMART101 in Pediatric and Adult Patients With Hematological Malignancies After T Cell Depleted Allo-HSCT
Is NCT04959903 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies Allogeneic T cell progenitors, cultured ex-vivo for hematological malignancies.
Treatment: Allogeneic T cell progenitors, cultured ex-vivo — The purpose of this study is to evaluate the safety and the efficacy of SMART101 (Human T Lymphoid Progenitor (HTLP)) injection to accelerate immune reconstitution after T cell depleted allogeneic hematopoietic stem cell transplantation (HSCT) in adult and pediatric patients with hematological malignancies.
Check if I qualifyExtracted eligibility criteria
Cancer type
Acute Myeloid Leukemia
Acute Lymphoblastic Leukemia
Non-Hodgkin Lymphoma
Multiple Myeloma
Myelodysplastic Syndrome
Chronic Lymphocytic Leukemia
Biomarker criteria
Allowed: TP53 any mutation
mutations of TP53
Prior therapy
Must have received: T cell depleted allogeneic hematopoietic stem cell transplantation
Patient eligible for a T-depleted allogeneic HSCT
Cannot have received: allogeneic stem cell transplantation
Prior therapy with allogeneic stem cell transplantation
Cannot have received: cellular therapy
Exception: within one month before inclusion
Treatment with another cellular therapy within one month before inclusion
Lab requirements
Blood counts
normal organ function prior to conditioning regimen
Kidney function
normal organ function prior to conditioning regimen
Liver function
normal organ function prior to conditioning regimen
Cardiac function
normal organ function prior to conditioning regimen
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Memorial Sloan Kettering Cancer Center (MSKCC) · New York, New York
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify